Peptide Stack for Injury Recovery: BPC-157 and TB-500 Protocol

Injury recovery is one of the most compelling use cases for therapeutic peptides. Unlike systemic supplements that work broadly, BPC-157 and TB-500 have specific, well-documented mechanisms that accelerate the biological processes underlying tissue repair. For athletes, active individuals, and anyone dealing with a persistent injury, this stack represents one of the most evidence-supported options available outside of pharmaceutical interventions.

Why BPC-157 and TB-500 Are the Healing Stack

BPC-157 (Body Protection Compound 157) is a 15-amino acid sequence derived from a protective protein found naturally in gastric juice. It has been studied in dozens of rodent models of injury — tendon ruptures, ligament tears, muscle lacerations, bone fractures, nerve damage, and more. The consistent finding is dramatically accelerated healing compared to control groups, often reaching statistical significance within weeks.

BPC-157 works through multiple mechanisms: it upregulates growth factor receptors (particularly VEGFR2 and FGFR), promotes angiogenesis (new blood vessel formation) at injury sites, stimulates fibroblast proliferation and migration, modulates nitric oxide signaling, and activates the FAK-paxillin pathway involved in cell adhesion and movement. It also has a strong record in gut healing research, making it valuable for athletes with GI issues that impair nutrient absorption and recovery.

TB-500 (Thymosin Beta-4) is a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. Its primary function in healing involves the regulation of actin — a structural protein essential to cell movement and wound healing. TB-500 facilitates cell migration into injury sites, reduces inflammation (particularly by downregulating fibrin accumulation and scar formation), and promotes the differentiation of stem cells in damaged tissue. Critically, TB-500 has a systemic distribution effect — it does not need to be injected directly at the injury site to reach it.

Together, BPC-157 and TB-500 work through complementary but non-overlapping pathways. BPC-157 is the stronger local signaling agent; TB-500 is superior for reducing inflammation, limiting scarring, and mobilizing systemic healing resources. Their combination produces additive effects — confirmed in multiple animal models comparing mono-therapy against combined therapy.

Loading and Maintenance Protocol

Acute Injury Phase (Weeks 1–4): Loading Doses

For a new or active injury, higher doses accelerate the initial repair cascade.

BPC-157

• Dose: 400–500 mcg per day
• Frequency: Once or twice daily (split the dose if using twice)
• Route: Subcutaneous injection as close to the injured area as practical (local proximity appears to enhance effect), or intramuscular for deep tissue injuries
• Oral: If GI involvement or systemic gut support is desired, add sublingual or oral BPC-157 at the same dose — it has oral bioavailability for gut-specific effects

TB-500

• Dose: 7.66 mg (one standard vial) per week during loading
• Frequency: Split into 2 injections per week (e.g., 3.83 mg on Monday and Thursday)
• Route: Subcutaneous injection
• Location: Site does not need to be proximal to injury — TB-500 distributes systemically

Maintenance Phase (Weeks 5–12): Reduced Doses

Once active healing is underway and acute symptoms have improved:

BPC-157

• Dose: 250–300 mcg per day
• Continue daily injections
• Reduce to 5 days on, 2 days off if preferred

TB-500

• Dose: 2–5 mg per week (1–2 injections)
• Maintain weekly dosing until full recovery is established

Injury-Specific Protocols

Different tissue types respond to slightly different approaches within this overall stack.

Tendon and Ligament Injuries Tendons and ligaments have poor blood supply and are notoriously slow to heal. BPC-157 has the most evidence for tendon recovery — it has been shown in animal models to fully restore Achilles tendon mechanical properties after surgical transection, outperforming corticosteroid injections significantly. TB-500 reduces the fibrous scar tissue that forms in ligaments and replaces functional connective tissue.

For tendon and ligament injuries, prioritize local BPC-157 injection near the affected area. Combine with collagen supplementation (10–15 g/day with vitamin C) to provide building blocks for tendon matrix synthesis. Eccentric loading exercises, introduced gradually, work synergistically with the peptides to organize newly synthesized collagen fibers correctly.

Muscle Tears and Strains BPC-157 has demonstrated accelerated muscle fiber regeneration in rat muscle injury models. TB-500 is particularly effective here — its actin-regulatory mechanism directly supports the myoblast (muscle progenitor cell) activity needed for muscle repair. For muscle injuries, twice-daily BPC-157 during the acute phase and weekly TB-500 is the standard approach. Active recovery (gentle movement within pain-free range) accelerates the healing more than complete rest.

Bone Fractures and Stress Fractures BPC-157 has been studied specifically for bone healing and shows positive effects on fracture consolidation in animal models. It promotes osteoblast activity and the vascularization necessary for bone remodeling. TB-500's anti-inflammatory effects reduce excessive periosteal inflammation that can slow healing. Combine with vitamin D3 (3,000–5,000 IU/day), vitamin K2 (200 mcg/day), and magnesium for comprehensive bone healing support.

Nerve Injuries Both peptides have neuroprotective and neuroregenerative properties. BPC-157 has been shown to promote sciatic nerve regeneration and reduce neurological deficits in crush injury models. TB-500 supports nerve repair through its role in cellular migration and anti-fibrotic effects. For nerve injuries, the protocol is similar but healing timelines are longer — expect meaningful improvement at 8–16 weeks rather than 4–6.

Spinal and Disc Issues BPC-157's potent anti-inflammatory effects and its activity on nitric oxide signaling make it relevant for disc herniation and spinal stenosis. Multiple case reports describe significant pain reduction and functional improvement. Oral or sublingual BPC-157 is often combined with subcutaneous injection for spinal conditions to maximize both systemic and gut-protective effects.

What to Expect: Recovery Timeline

Week 1–2: Reduction in acute inflammation and pain. Many users report this within the first week, particularly with BPC-157. Sleep quality often improves as pain disruptions decrease.

Week 3–4: Functional range of motion begins to improve. Swelling decreases. For muscle injuries, strength returns more rapidly than with peptide-free recovery. Tendons remain fragile at this stage — do not return to full loading prematurely.

Week 5–8: Significant structural repair is underway. Physical therapy exercises can be progressed more aggressively. For tendon and ligament injuries, adequate tensile strength is typically achieved in this window, though full maturation takes longer.

Week 8–12: Most acute injuries should be functionally resolved with this protocol. Residual stiffness and reduced tensile strength in tendons may persist — the maintenance protocol supports continued remodeling through this phase.

For a complementary approach to recovery optimization, see our sleep and recovery peptide stack, which addresses the hormonal environment that supports tissue repair overnight.

Important Considerations

Physical therapy is not optional. Peptides accelerate healing, but they do not replace the mechanical loading signals that direct collagen fiber organization. Unstructured collagen laid down without appropriate loading creates weaker scar tissue. Work with a physical therapist to implement progressive loading as healing progresses.

Imaging confirmation. For significant injuries, baseline ultrasound or MRI imaging allows objective tracking of structural improvement. This is particularly valuable for tendon tears and muscle injuries where the extent of damage affects protocol decisions.

Avoid NSAIDs during the protocol. NSAIDs (ibuprofen, naproxen) inhibit prostaglandin synthesis, which is required for early phases of tissue healing. They are counterproductive when combined with a healing peptide stack. Consider acetaminophen for pain management if needed, or low-dose aspirin if inflammation management is specifically required.

Frequently Asked Questions

Q: Does BPC-157 need to be injected near the injury to work? Proximity matters and appears to enhance local effects, but BPC-157 has systemic circulation and subcutaneous injection anywhere in the body will produce some benefit. For joint and tendon injuries, many practitioners recommend injecting within 3–4 cm of the affected site when possible. For gut and systemic effects, injection site is less critical.

Q: How long should I run the full injury stack? Most injuries respond well within 8–12 weeks of the combined BPC-157 + TB-500 protocol. Chronic or severe injuries may warrant extending to 16 weeks. Once fully healed, a short maintenance cycle of BPC-157 alone at 250 mcg/day for 4 weeks can be used to reinforce repair before returning to high-load activity.

Q: Can I use this stack alongside other peptides? Yes. The injury recovery stack is commonly combined with ipamorelin (for enhanced GH-driven repair signaling) or with the women's peptide stack protocol. See our peptide stacking rules and safety guide for guidance on combining peptides safely.

Q: Is TB-500 banned in sports? Yes. TB-500 (thymosin beta-4) is prohibited by WADA both in and out of competition under the category of peptide hormones, growth factors, related substances, and mimetics. Competitive athletes subject to drug testing should not use this compound.

Q: What's the difference between TB-500 and full thymosin beta-4? Technically, TB-500 is a fragment of the full thymosin beta-4 protein — specifically the actin-binding domain. Most commercially available TB-500 is this fragment rather than the full peptide. The fragment retains most of the healing properties while being more stable and easier to produce. For practical purposes in injury recovery, the terms are often used interchangeably by suppliers.